ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity.

Kirsten Richter1, Nicole Egli1, Laetitia Petersen1, Patrizia Murer1, Andreas Katopodis1, Christoph Huber1
1Anaveon, Basel Switzerland

Results

ANV419 treatment leads to similar regulation of NK receptors compared to IL-2 and IL-15

ANV419 amplifies NK cell mediated killing independent of FcγR3a SNP F158V

ANV419 enhances tumor growth inhibition in combination with PD1 or CTLA4 blockade in the syngeneic H22 mouse model

Conclusions

- The data presented here support the initiation of clinical phase 2 studies assessing ANV419 treatment in indications in which NK and CD8 T cells are involved in tumor resolution as monotherapy and in combination with ADCC inducing treatments or checkpoint inhibitors.
- Please visit poster 749P for more information on our phase 1 data.

ESMO Annual Meeting 2022